Literature review and case report on the use of rezafungin for spondylodiscitis in an outpatient parenteral antimicrobial therapy (OPAT) setting

Bone and joint infections secondary to Candida species are associated with high morbidity and mortality, requiring extended courses of antifungal therapy, with parenteral medications being first-line therapy. The reported use of antifungals in outpatient parenteral antimicrobial therapy (OPAT) for deep-seated bone and joint infections is limited. We report and discuss the use of rezafungin, a novel long-acting echinocandin, in an OPAT setting for spondylodiscitis secondary to Candida albicans.